3,704 reports of this reaction
1.3% of all ADALIMUMAB AATY reports
#15 most reported adverse reaction
ALOPECIA is the #15 most commonly reported adverse reaction for ADALIMUMAB AATY, manufactured by CELLTRION USA, Inc.. There are 3,704 FDA adverse event reports linking ADALIMUMAB AATY to ALOPECIA. This represents approximately 1.3% of all 280,977 adverse event reports for this drug.
Patients taking ADALIMUMAB AATY who experience alopecia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALOPECIA is a less commonly reported adverse event for ADALIMUMAB AATY, but still significant enough to appear in the safety profile.
In addition to alopecia, the following adverse reactions have been reported for ADALIMUMAB AATY:
The following drugs have also been linked to alopecia in FDA adverse event reports:
ALOPECIA has been reported as an adverse event in 3,704 FDA reports for ADALIMUMAB AATY. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALOPECIA accounts for approximately 1.3% of all adverse event reports for ADALIMUMAB AATY, making it a notable side effect.
If you experience alopecia while taking ADALIMUMAB AATY, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.